Nektar Therapeutics (San Carlos, CA) will work with subsidiaries of Baxter International, Inc. (Deerfield, IL), to develop new PEGylated therapeutics for hemophilia.
Nektar Therapeutics (San Carlos, CA), will work with subsidiaries of Baxter International, Inc. (Deerfield, IL), to develop new PEGylated therapeutics for hemophilia. The program will begin preclinical development in 2008.
Under the terms of the agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during research, clinical development, and commercialization. Nektar will also receive royalties on end product sales.
Baxter will be responsible for the development and commercialization of the product and Nektar will be responsible for the technology development used in the product, including the provision of clinical and commercial PEG reagents.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.